Please Wait.....
Report
Europe Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2022-11-01 I 259 Pages I Data Bridge Market Research
The Europe lung cancer diagnostics market is projected to register a substantial CAGR of 13.3% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030
Market Segmentation:
Europe Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the Europe lung cancer diagnostics market are:
- Rise in market players and the availability of advanced services
- Increase in awareness about the lung cancer diagnostics
Market Players:
Some of the major players operating in the Europe lung cancer diagnostics market are:
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott
- Quest Diagnostics Incorporated
- Bio-Rad Laboratories, Inc.
- Biocartis
- Danaher
- DiaSorin S.p.A.
- Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)
- Inivata Ltd.
- Myriad Genetics, Inc.
- NeoGenomics Laboratories
- PerkinElmer Inc.
- Vela Diagnostics
- QIAGEN
- Siemens Healthcare GmbH
- Veracyte, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 28
1.1 OBJECTIVES OF THE STUDY 28
1.2 MARKET DEFINITION 28
1.3 OVERVIEW OF EUROPE LUNG CANCER DIAGNOSTICS MARKET 28
1.4 LIMITATIONS 30
1.5 MARKETS COVERED 30
2 MARKET SEGMENTATION 33
2.1 MARKETS COVERED 33
2.2 GEOGRAPHICAL SCOPE 34
2.3 YEARS CONSIDERED FOR THE STUDY 35
2.4 CURRENCY AND PRICING 35
2.5 DBMR TRIPOD DATA VALIDATION MODEL 36
2.6 MULTIVARIATE MODELLING 39
2.7 PRODUCT TYPE LIFELINE CURVE 39
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41
2.9 DBMR MARKET POSITION GRID 42
2.10 MARKET TESTING TYPE COVERAGE GRID 44
2.11 VENDOR SHARE ANALYSIS 45
2.12 SECONDARY SOURCES 46
2.13 ASSUMPTIONS 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 50
4.1 PORTER'S FIVE FORCES 51
4.2 PESTEL ANALYSIS 52
4.3 INDUSTRY INSIGHTS 53
5 EPIDERMIOLOGY 54
6 REGULATIONS 55
7 MARKET OVERVIEW 58
7.1 DRIVERS 60
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 60
7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER 61
7.1.3 INCREASING CASES OF LUNG CANCER 63
7.1.4 RISE IN PRODUCT APPROVALS 63
7.2 RESTRAINTS 65
7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER 65
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY 65
7.3 OPPORTUNITIES 67
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 67
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 67
7.3.3 RISING AWARENESS OF LUNG CANCER 68
7.4 CHALLENGES 69
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 69
7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 69
7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 70
8 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 71
8.1 OVERVIEW 72
8.2 INSTRUMENTS 75
8.2.1 IMAGING INSTRUMENTS 76
8.2.1.1 CT SYSTEMS 76
8.2.1.2 ULTRASOUND SYSTEMS 76
8.2.1.3 MRI SYSTEMS 76
8.2.1.4 OTHERS 76
8.2.2 BIOPSY INSTRUMENTS 77
8.2.2.1 NEEDLE BIOPSY 77
8.2.2.2 ENDOSCOPIC BIOPSY 77
8.2.2.3 CORE BIOPSY 77
8.2.2.4 OTHERS 77
8.2.3 PATHOLOGY-BASED INSTRUMENTS 78
8.2.3.1 SLIDE STAINING SYSTEMS 78
8.2.3.2 TISSUE PROCESSING SYSTEMS 78
8.2.3.3 CELL PROCESSORS 78
8.2.3.4 PCR INSTRUMENTS 78
8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS 78
8.3 CONSUMABLES AND ACCESSORIES 79
8.3.1 KITS 80
8.3.1.1 DNA POLYMERASE KITS 80
8.3.1.2 NUCLEIC ACID ISOLATION KITS 80
8.3.1.3 PCR KITS 80
8.3.1.4 OTHERS 80
8.3.2 REAGENTS 81
8.3.2.1 ASSAYS 81
8.3.2.2 BUFFERS 81
8.3.2.3 PRIMERS 81
8.3.2.4 OTHERS 81
8.3.3 PROBES 82
8.3.4 OTHER CONSUMABLES 82
9 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE 83
9.1 OVERVIEW 84
9.2 IMAGING TEST 87
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 88
9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 88
9.2.3 CHEST X-RAY 88
9.2.4 BONE SCAN 88
9.2.5 MRI 88
9.2.6 OTHERS 88
9.3 BIOMARKERS TEST 89
9.3.1 EGFR MUTATION TEST 90
9.3.2 KRAS MUTATION TEST 90
9.3.3 ALK TEST 90
9.3.4 HER2 TEST 90
9.3.5 OTHERS 91
9.4 BIOPSY 91
9.4.1 NEEDLE BIOPSY 92
9.4.2 BRONCHOSCOPY BIOPSY 92
9.4.3 CORE BIOPSY 92
9.4.4 OTHERS 92
9.5 BLOOD TEST 92
9.5.1 COMPLETE BLOOD COUNT (CBC) 93
9.5.2 BLOOD CHEMISTRY TESTS 93
9.5.3 OTHERS 93
9.6 OTHERS 94
10 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 95
10.1 OVERVIEW 96
10.2 NON-SMALL CELL LUNG CANCER 99
10.3 SMALL CELL LUNG CANCER 100
11 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY END USER 101
11.1 OVERVIEW 102
11.2 HOSPITAL 105
11.3 ASSOCIATED LABS 105
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES 106
11.5 DIAGNOSTIC IMAGING CENTERS 107
11.6 CANCER RESEARCH INSTITUTES 107
11.7 OTHERS 108
12 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 109
12.1 OVERVIEW 110
12.2 DIRECT TENDER 113
12.3 RETAIL SALES 114
13 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY REGION 115
13.1 EUROPE 116
13.1.1 GERMANY 126
13.1.2 U.K. 131
13.1.3 FRANCE 136
13.1.4 ITALY 141
13.1.5 SPAIN 146
13.1.6 RUSSIA 151
13.1.7 NETHERLANDS 156
13.1.8 SWITZERLAND 161
13.1.9 TURKEY 166
13.1.10 BELGIUM 171
13.1.11 POLAND 176
13.1.12 DENMARK 181
13.1.13 SWEDEN 186
13.1.14 NORWAY 191
13.1.15 FINLAND 196
13.1.16 REST OF EUROPE 201
14 EUROPE LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 202
14.1 COMPANY SHARE ANALYSIS: EUROPE 202
15 SWOT ANALYSIS 203
16 COMPANY PROFILE 204
16.1 F. HOFFMANN-LA ROCHE LTD. (2022) 204
16.1.1 COMPANY SNAPSHOT 204
16.1.2 REVENUE ANALYSIS 204
16.1.3 COMPANY SHARE ANALYSIS 205
16.1.4 PRODUCT PORTFOLIO 205
16.1.5 RECENT DEVELOPMENTS 205
16.2 THERMO FISHER SCIENTIFIC INC. (2022) 206
16.2.1 COMPANY SNAPSHOT 206
16.2.2 REVENUE ANALYSIS 206
16.2.3 COMPANY SHARE ANALYSIS 207
16.2.4 PRODUCT PORTFOLIO 207
16.2.5 RECENT DEVELOPMENTS 207
16.3 ABBOTT (2022) 208
16.3.1 COMPANY SNAPSHOT 208
16.3.2 REVENUE ANALYSIS 208
16.3.3 COMPANY SHARE ANALYSIS 209
16.3.4 PRODUCT PORTFOLIO 209
16.3.5 RECENT DEVELOPMENTS 209
16.4 QUEST DIAGNOSTICS INCORPORATED (2022) 210
16.4.1 COMPANY SNAPSHOT 210
16.4.2 REVENUE ANALYSIS 210
16.4.3 COMPANY SHARE ANALYSIS 211
16.4.4 PRODUCT PORTFOLIO 211
16.4.5 RECENT DEVELOPMENTS 213
16.5 BIODESIX (2022) 214
16.5.1 COMPANY PROFILE 214
16.5.2 REVENUE ANALYSIS 214
16.5.3 COMPANY SHARE ANALYSIS 215
16.5.4 PRODUCT PORTFOLIO 215
16.5.5 RECENT DEVELOPMENTS 215
16.6 AMOY DIAGNOSTICS CO., LTD. (2022) 216
16.6.1 COMPANY SNAPSHOT 216
16.6.2 PRODUCT PORTFOLIO 216
16.6.3 RECENT DEVELOPMENTS 216
16.7 BIO-RAD LABORATORIES, INC. (2022) 217
16.7.1 COMPANY SNAPSHOT 217
16.7.2 REVENUE ANALYSIS 217
16.7.3 PRODUCT PORTFOLIO 218
16.7.4 RECENT DEVELOPMENTS 218
16.8 BIOCARTIS (2022) 219
16.8.1 COMPANY SNAPSHOT 219
16.8.2 REVENUE ANALYSIS 219
16.8.3 PRODUCT PORTFOLIO 220
16.8.4 RECENT DEVELOPMENTS 220
16.9 BODITECH MED INC. 221
16.9.1 COMPANY PROFILE 221
16.9.2 PRODUCT PORTFOLIO 221
16.9.3 RECENT DEVELOPMENTS 221
16.10 DANAHER (2022) 222
16.10.1 COMPANY SNAPSHOT 222
16.10.2 REVENUE ANALYSIS 222
16.10.3 PRODUCT PORTFOLIO 223
16.10.4 RECENT DEVELOPMENTS 223
16.11 DIASORIN S.P.A. (2022) 224
16.11.1 COMPANY SNAPSHOT 224
16.11.2 REVENUE ANALYSIS 224
16.11.3 PRODUCT PORTFOLIO 225
16.11.4 RECENT DEVELOPMENTS 225
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022) 226
16.12.1 COMPANY SNAPSHOT 226
16.12.2 REVENUE ANALYSIS 226
16.12.3 PRODUCT PORTFOLIO 227
16.12.4 RECENT DEVELOPMENTS 227
16.13 20/20 GENE SYSTEMS 228
16.13.1 COMPANY PROFILE 228
16.13.2 PRODUCT PORTFOLIO 228
16.13.3 RECENT DEVELOPMENTS 228
16.14 GUARDANT HEALTH INC. 229
16.14.1 COMPANY PROFILE 229
16.14.2 PRODUCT PORTFOLIO 229
16.14.3 RECENT DEVELOPMENTS 229
16.15 INIVATA LTD. 230
16.15.1 COMPANY PROFILE 230
16.15.2 PRODUCT PORTFOLIO 230
16.15.3 RECENT DEVELOPMENTS 230
16.16 LALPATHLABS.COM (2022) 231
16.16.1 COMPANY SNAPSHOT 231
16.16.2 REVENUE ANALYSIS 231
16.16.3 PRODUCT PORTFOLIO 232
16.16.4 RECENT DEVELOPMENTS 233
16.17 LUNGLIFE AI, INC. (2022) 234
16.17.1 COMPANY SNAPSHOT 234
16.17.2 PRODUCT PORTFOLIO 234
16.17.3 RECENT DEVELOPMENTS 234
16.18 MEDGENOME 235
16.18.1 COMPANY SNAPSHOT 235
16.18.2 PRODUCT PORTFOLIO 235
16.18.3 RECENT DEVELOPMENTS 236
16.19 MYRIAD GENETICS, INC. 237
16.19.1 COMPANY SNAPSHOT 237
16.19.2 PRODUCT PORTFOLIO 237
16.19.3 RECENT DEVELOPMENTS 237
16.20 NEOGENOMICS LABORATORIES (2022) 238
16.20.1 COMPANY SNAPSHOT 238
16.20.2 REVENUE ANALYSIS 238
16.20.3 PRODUCT PORTFOLIO 239
16.20.4 RECENT DEVELOPMENTS 239
16.21 NANOSTRING (2022) 240
16.21.1 COMPANY SNAPSHOT 240
16.21.2 REVENUE ANALYSIS 240
16.21.3 PRODUCT PORTFOLIO 241
16.21.4 RECENT DEVELOPMENTS 241
16.22 NANOENTEK 242
16.22.1 COMPANY PROFILE 242
16.22.2 PRODUCT PORTFOLIO 242
16.22.3 RECENT DEVELOPMENTS 242
16.23 ONCOCYTE CORPORATION 243
16.23.1 COMPANY PROFILE 243
16.23.2 SERVICE PORTFOLIO 243
16.23.3 RECENT DEVELOPMENTS 243
16.24 PERKINELMER INC 244
16.24.1 COMPANY PROFILE 244
16.24.2 REVENUE ANALYSIS 244
16.24.3 PRODUCT PORTFOLIO 245
16.25 PLEXBIO 246
16.25.1 COMPANY SNAPSHOT 246
16.25.2 PRODUCT PORTFOLIO 246
16.25.3 RECENT DEVELOPMENTS 246
16.26 QIAGEN 247
16.26.1 COMPANY SNAPSHOT 247
16.26.2 REVENUE ANALYSIS 247
16.26.3 PRODUCT PORTFOLIO 248
16.26.4 RECENT DEVELOPMENTS 248
16.27 SIEMENS HEALTHCARE GMBH 249
16.27.1 COMPANY SNAPSHOT 249
16.27.2 REVENUE ANALYSIS 249
16.27.3 PRODUCT PORTFOLIO 250
16.27.4 RECENT DEVELOPMENTS 250
16.28 VERACYTE, INC. (2022) 251
16.28.1 COMPANY SNAPSHOT 251
16.28.2 REVENUE ANALYSIS 251
16.28.3 PRODUCT PORTFOLIO 252
16.28.4 RECENT DEVELOPMENTS 252
16.29 VELA DIAGNOSTICS 253
16.29.1 COMPANY PROFILE 253
16.29.2 PRODUCT PORTFOLIO 253
16.29.3 RECENT DEVELOPMENTS 255
17 QUESTIONNAIRE 256
18 RELATED REPORTS 259
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security